CompletedPHASE2, PHASE3NCT04516096

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Amylyx Pharmaceuticals Inc.
Principal Investigator
Machelle Manual, PhD
Amylyx Pharmaceuticals Inc.
Intervention
AMX0035(drug)
Enrollment
28 enrolled
Eligibility
18 years · All sexes
Timeline
20202023

Study locations (5)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04516096 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials